Cytotoxicity screening of emulsifiers for pulmonary application of lipid nanoparticles

Steiner, Verena; Öhlinger, Kristin; Corzo, Carolina; Salar-Behzadi, Sharareh; Frőhlich, Eleonore

doi:10.1016/j.ejps.2019.104968

Cited by 13 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poloxamers are amphiphatic polymers of polyoxypropylene and polyoxyethylene that were shown to increase the diffusion rate of coated SLNs across artificial sputum media in vitro compared with uncoated SLNs [ 149 ]. Another study confirmed that poloxamer showed no cytotoxicity in cultured human alveolar epithelial cells, making it suitable for pulmonary applications [ 150 ]. A team in 2020 demonstrated that short bacteriophage heptapeptides screened from a phage display library also had the ability to improve particle transport across ex vivo CF mucus [ 148 ].…”

Section: Challenges Of Inhaled Lnp Therapeutics and Design Considerat...mentioning

confidence: 99%

“…Additionally, toxicology tests aimed at the pulmonary administration route need to cover particle morphology, size distribution, surface chemistry and agglomeration tendency, which goes beyond classical toxicology tests focused on drug dose and composition [ 26 ]. Steiner et al recently incorporated three orally-approved excipients: Kolliphor RH40Poloxamer 188 and Tween 80, into drug-loaded SLNs in vitro [ 150 ]. These particles demonstrated low toxicity and suitability for pulmonary applications in cultured human alveolar epithelial cells and macrophages [ 150 ].…”

Section: Challenges Of Inhaled Lnp Therapeutics and Design Considerat...mentioning

confidence: 99%

See 1 more Smart Citation

Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics

Leong

2022

Biomedicines

View full text Add to dashboard Cite

Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery. With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 pandemic, investigations into applying LNPs to deliver inhaled therapeutics directly to the lungs are underway. The progress in LNP development as well as the recent pre-clinical studies in three main classes of inhaled encapsulated drugs: small molecules, nucleic acids and proteins/peptides will be discussed. The advantages of the pulmonary drug delivery system such as reducing systemic toxicity and enabling higher local drug concentration in the lungs are evaluated together with the challenges and design considerations for improved formulations. This review provides a perspective on the future prospects of LNP-mediated delivery of inhaled therapeutics for respiratory diseases.

show abstract

Section: Challenges Of Inhaled Lnp Therapeutics and Design Considerat...mentioning

confidence: 99%

Section: Challenges Of Inhaled Lnp Therapeutics and Design Considerat...mentioning

confidence: 99%

Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics

Leong

2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Thus, human cells tend to be better appropriate for screening adverse effects in the human lungs. 293 As cellulose nanocrystals (CNCs) expand in the generation, promoting healthy employment practices will be crucial to distance control and development. Particles other than CNCs with comparable high aspect ratios demonstrated inhalation toxicity.…”

Section: Toxicity Of Inhaled Nanoparticlesmentioning

confidence: 99%

“…Due to the specific advantages, i.e., lower proliferation rate, more extensive cell size, human cells displayed lower cytotoxicity than murine cells. Thus, human cells tend to be better appropriate for screening adverse effects in the human lungs . As cellulose nanocrystals (CNCs) expand in the generation, promoting healthy employment practices will be crucial to distance control and development.…”

Section: Toxicity Of Inhaled Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases

Pramanik

Mohanto

Manne³

et al. 2021

Mol. Pharmaceutics

View full text Add to dashboard Cite

Chronic pulmonary diseases encompass different persistent and lethal diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), asthma, and lung cancers that affect millions of people globally. Traditional pharmacotherapeutic treatment approaches (i.e., bronchodilators, corticosteroids, chemotherapeutics, peptide-based agents, etc.) are not satisfactory to cure or impede diseases. With the advent of nanotechnology, drug delivery to an intended site is still difficult, but the nanoparticle’s physicochemical properties can accomplish targeted therapeutic delivery. Based on their surface, size, density, and physical-chemical properties, nanoparticles have demonstrated enhanced pharmacokinetics of actives, achieving the spotlight in the drug delivery research field. In this review, the authors have highlighted different nanoparticle-based therapeutic delivery approaches to treat chronic pulmonary diseases along with the preparation techniques. The authors have remarked the nanosuspension delivery via nebulization and dry powder carrier is further effective in the lung delivery system since the particles released from these systems are innumerable to composite nanoparticles. The authors have also outlined the inhaled particle’s toxicity, patented nanoparticle-based pulmonary formulations, and commercial pulmonary drug delivery devices (PDD) in other sections. Recently advanced formulations employing nanoparticles as therapeutic carriers for the efficient treatment of chronic pulmonary diseases are also canvassed.

show abstract

“…Most of the studies about the pulmonary route of administration have used aerosol formulations that have been very effective for the treatment of respiratory inflammation and other lung disorders [65]. This pathway represents a possibility for systemic and non-invasive release of proteases [66]. Another therapeutic route is the transdermal one, which uses adhesives and is a painless alternative to injections.…”

Section: Formulation Of Proteasesmentioning

confidence: 99%

Plant Therapeutic Proteases: Chemical Aspects, Applications and Pharmaceutical Formulations

Ferreira¹,

Silva-López²

2021

EJMP

View full text Add to dashboard Cite

Background: Plants are important sources of therapeutic proteases with expressive activity, stability, specificity, and efficiency. These proteases are employed at low concentrations and produce lesser side effects. They have complex tridimensional structures whose maintenance is a challenge, requiring specific conditions to guarantee the biological and pharmacological activities of these compounds. Aims: To conduct a literature review about plant therapeutic proteases, their principal biochemical aspects, potentials and clinical applications, and main pharmaceutical formulations. Materials and Methods: The present study consisted of a bibliographic survey of the major plant therapeutic proteases. An investigation was performed in the PUBMED, SciELO, ScienceDirect and Academic Google databases using the keywords plant enzymes, therapeutic protease, immobilization, formulation. Results: Some plant therapeutic proteases, such as papain and bromelain, are employed to treat many diseases and conditions, but the complexity of their structures is an important limitation of their uses. Thus, the structure and activities of their formulations need to be stabilized and protected against degradation, with improved pharmacokinetics, a prolonged time of action, reduced toxic effects, and proper direction towards their therapeutic target. Nanotechnology has made it possible to manufacture drug carriers such as polymeric nano- and microparticles, hydrogels, dendrimers and liposomes which are able to increase their efficacy and clinical applicability, as well as patient compliance. Sustainability initiatives that use Green Chemistry together with nanobiotechnology have managed to reduce the risks of toxicity to organisms and the environment. Green synthesis uses lower concentrations of metal ions, water-soluble, biocompatible and non-toxic compounds, as well as seeking energy efficiency and using renewable sources of raw materials. Conclusions: Investigations about new formulations of plant therapeutic proteases using biodegradable and biocompatible polymers is of great biomedical interest because they generate less toxic new biopharmaceuticals, in addition to protecting and stabilizing the enzymatic structure.

show abstract

Cytotoxicity screening of emulsifiers for pulmonary application of lipid nanoparticles

Cited by 13 publications

References 21 publications

Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics

Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics

Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases

Plant Therapeutic Proteases: Chemical Aspects, Applications and Pharmaceutical Formulations

Contact Info

Product

Resources

About